SCHEMBL5887026

SCHEMBL5887026

ClC1=C(c2ccc(Cl)cc2Cl)[CH]CC=C1c1ccc(Cl)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHR P35869 6/20 0.40
TP53 P04637 2/20 0.40
EIF4E P06730 1/20 0.34
HSD11B1 P28845 1/20 0.33
SRD5A2 P31213 1/20 0.33
CYP1B1 Q16678 1/20 0.33
PGR P06401 2/20 0.32
ALKBH3 Q96Q83 1/20 0.32
PTGS2 P35354 1/20 0.32
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31
NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887296 0.90 AHR (0.37) AHRTP53EIF4ECYP1B1PGR
SCHEMBL5887211 0.76 CYP2A6 (0.40) KDM4ENPC1RAB9A
SCHEMBL5887212 0.74 ALKBH3 (0.39) AHRCYP1B1ALKBH3KDM4ERAB9A
SCHEMBL5887298 0.73 RAD51 (0.40) AHRTP53ALKBH3
SCHEMBL4447113 0.72 AHR (0.65) AHRTP53EIF4EHSD11B1SRD5A2
SCHEMBL5887318 0.70 BCL2L1 (0.37) AHREIF4EKDM4ENPC1RAB9A
SCHEMBL29456490 0.68 AHR (0.69) AHRTP53EIF4EHSD11B1SRD5A2
SCHEMBL5886910 0.66 HSD17B10 (0.38) AHRCYP1B1
SCHEMBL4811189 0.65 PTGS2 (0.38) PTGS2KDM4ERAB9A
SCHEMBL5887415 0.65 AHR (0.38) AHRCYP1B1ALKBH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R AHR 16/4885TP53 4563/4885EIF4E 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.